FindTrial
Sign In

Irisin in PCOS and its change with metformin therapy.

A comprehensive study of Serum Irisin and AMH in PCOS patients, its correlation with hormonal profile and markers of insulin resistance including change of irisin with metformin therapy - IRISIN IN PCOS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050982
Enrollment
87
Registered
2023-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: metformin: metformin in pcos Intervention2: metformin: Tab.Metformin will be given to eligible pcos patients. Metformin 500 mg started twice daily after food orally.It will be increase

Sponsors

TELAGAREDDY RADHA KRISHNA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Confirmed cases of PCOS 2. Age 18â??40 years 3. All PCOS women who did not receive oral contraceptives, insulin-sensitizing agents, antiandrogens, or glucocorticoids in the past 3 months. 4. Age and sex matched healthy adults are included in control group

Exclusion criteria

Exclusion criteria: 1. Other causes for hyperandrogenemia and ovulatory dysfunction including a. 21-alpha hydroxylase deficiency, b. Congenital adrenal hyperplasia, and c. Cushingâ??s syndrome 2. T1DM 3. T2DM 4. Smokers. 5. Alcoholics. 6. Medicines that affect glucose/lipids/androgen metabolism within past 3 months.

Design outcomes

Primary

MeasureTime frame
LEVELS OF IRSIN IN PCOS CHANGE IN IRISIN WITH METFORMINTimepoint: 6 MONTHS—

Secondary

MeasureTime frame
CHANGE IN IRISIN WITH METFORMINTimepoint: 6 months—

Countries

India

Contacts

Public ContactTelagareddy Radhakrishna

Berhampur University

mkcgendocrinology@gmail.com9437028770

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026